氯胺酮治疗创伤后应激障碍:领域现状。

Focus (American Psychiatric Publishing) Pub Date : 2023-07-01 Epub Date: 2023-06-28 DOI:10.1176/appi.focus.20230006
Rachel Fremont, Oneysha Brown, Adriana Feder, James Murrough
{"title":"氯胺酮治疗创伤后应激障碍:领域现状。","authors":"Rachel Fremont, Oneysha Brown, Adriana Feder, James Murrough","doi":"10.1176/appi.focus.20230006","DOIUrl":null,"url":null,"abstract":"<p><p>Posttraumatic stress disorder (PTSD) is a chronic and debilitating condition. Although several psychotherapeutic and pharmacological treatments are recommended for PTSD, many individuals do not respond to treatment or respond only partially, highlighting a critical need for additional treatments. Ketamine has the potential to address this therapeutic need. This review discusses how ketamine emerged as a rapid-acting antidepressant and has become a potential treatment for PTSD. A single dose of intravenous (IV) ketamine has been shown to facilitate rapid reduction of PTSD symptoms. Repeated IV ketamine administration significantly improved PTSD symptoms, compared with midazolam, in a predominantly civilian sample of individuals with PTSD. However, in a veteran and military population, repeated IV ketamine did not significantly reduce PTSD symptoms. Further study of ketamine as a treatment for PTSD is necessary, including which populations benefit most from this therapy and the potential benefits of combining psychotherapy and ketamine.</p>","PeriodicalId":73036,"journal":{"name":"Focus (American Psychiatric Publishing)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316217/pdf/","citationCount":"0","resultStr":"{\"title\":\"Ketamine for Treatment of Posttraumatic Stress Disorder: State of the Field.\",\"authors\":\"Rachel Fremont, Oneysha Brown, Adriana Feder, James Murrough\",\"doi\":\"10.1176/appi.focus.20230006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Posttraumatic stress disorder (PTSD) is a chronic and debilitating condition. Although several psychotherapeutic and pharmacological treatments are recommended for PTSD, many individuals do not respond to treatment or respond only partially, highlighting a critical need for additional treatments. Ketamine has the potential to address this therapeutic need. This review discusses how ketamine emerged as a rapid-acting antidepressant and has become a potential treatment for PTSD. A single dose of intravenous (IV) ketamine has been shown to facilitate rapid reduction of PTSD symptoms. Repeated IV ketamine administration significantly improved PTSD symptoms, compared with midazolam, in a predominantly civilian sample of individuals with PTSD. However, in a veteran and military population, repeated IV ketamine did not significantly reduce PTSD symptoms. Further study of ketamine as a treatment for PTSD is necessary, including which populations benefit most from this therapy and the potential benefits of combining psychotherapy and ketamine.</p>\",\"PeriodicalId\":73036,\"journal\":{\"name\":\"Focus (American Psychiatric Publishing)\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316217/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Focus (American Psychiatric Publishing)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1176/appi.focus.20230006\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/6/28 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Focus (American Psychiatric Publishing)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1176/appi.focus.20230006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/6/28 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

创伤后应激障碍(PTSD)是一种使人衰弱的慢性疾病。尽管针对创伤后应激障碍推荐了多种心理治疗和药物治疗方法,但许多患者对治疗没有反应或仅有部分反应,这凸显了对其他治疗方法的迫切需求。氯胺酮有可能满足这一治疗需求。本综述将讨论氯胺酮是如何作为一种速效抗抑郁剂出现并成为创伤后应激障碍的一种潜在治疗方法的。研究表明,单剂量静脉注射氯胺酮可迅速减轻创伤后应激障碍症状。在以平民为主的创伤后应激障碍患者样本中,与咪达唑仑相比,重复静脉注射氯胺酮能明显改善创伤后应激障碍症状。然而,在退伍军人和军人群体中,重复静脉注射氯胺酮并不能明显减轻创伤后应激障碍症状。有必要对氯胺酮作为创伤后应激障碍的治疗方法进行进一步研究,包括哪些人群从这种疗法中获益最多,以及心理疗法与氯胺酮相结合的潜在益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Ketamine for Treatment of Posttraumatic Stress Disorder: State of the Field.

Posttraumatic stress disorder (PTSD) is a chronic and debilitating condition. Although several psychotherapeutic and pharmacological treatments are recommended for PTSD, many individuals do not respond to treatment or respond only partially, highlighting a critical need for additional treatments. Ketamine has the potential to address this therapeutic need. This review discusses how ketamine emerged as a rapid-acting antidepressant and has become a potential treatment for PTSD. A single dose of intravenous (IV) ketamine has been shown to facilitate rapid reduction of PTSD symptoms. Repeated IV ketamine administration significantly improved PTSD symptoms, compared with midazolam, in a predominantly civilian sample of individuals with PTSD. However, in a veteran and military population, repeated IV ketamine did not significantly reduce PTSD symptoms. Further study of ketamine as a treatment for PTSD is necessary, including which populations benefit most from this therapy and the potential benefits of combining psychotherapy and ketamine.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Anorexia Nervosa Across the Lifespan: A Review of Recent Literature. Avoidant/Restrictive Food Intake Disorder: Review and Recent Advances. Building Confidence in Discussing Genetics With Patients With Eating Disorders and Their Families. Bulimia Nervosa and Binge-Eating Disorder Across the Lifespan. Charting a Path Toward Improving Detection and Clinical Outcomes for Eating Disorders in Cismales and Gender-Diverse Patients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1